^
Association details:
| Biomarker: | BRCA2 expression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
COMBINED TARGETING DNA DAMAGE RESPONSE AND ANTI-APOPTOTIC PROGRAMS IN AML
Published date:
05/14/2020
Excerpt:
Of note, although the combined treatment was most effective in cells with low or even undetectable BRCA1 or BRCA2 protein expression, cell lines with BRCA1 and BRCA2 expression also showed promising responses.
